Insights Category: Blog

Dual Targets, Double Impact: Advancing HER2 x TROP2 Bispecific ADCs in Preclinical Development

Homing in on the tumor: the magic bullet of cancer therapy Antibody-drug conjugates (ADCs) have revolutionized oncotherapy, achieving significant clinical success in multiple cancer types. Hailed as a “magic bullet” of precision medicine, ADCs improved therapeutic success in oncology, offering

Impact Starts in the Lab: Using Preclinical Models to Combat Autoimmune & Autoinflammatory Arthritis

Invisible and misunderstood: how it is to live with an autoimmune disease? “I think the hardest part of having an autoimmune disease is spending any free time I have sick in bed due to using up what little energy I

From Mutation to Metastasis: Preclinical Assay Platform for KRAS G12C Targeted Therapy

Three-decade long saga brings promise and breakthrough for better therapies Kirsten rat sarcoma (KRAS) has been long recognized as the most commonly mutated protooncogene, and under active exploration in cancer research for the past 30 years. The target has been

START YOUR JOURNEY
Phase
Modality
Therapeutic Area